{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"}],"units":"Participants"}],"description":"The percentage of participants who died from any cause was reported.","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"NUMBER","populationDescription":"Cohort 2 ITT population","reportingStatus":"POSTED","timeFrame":"Baseline until death (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)","title":"Percentage of Participants Who Died","type":"SECONDARY","unitOfMeasure":"percentage of participants"}